Dr. Daniel Y. Wang
Founder and CEO of Medinoah
PhD in Organic Chemistry, University of Delaware, USA
Dr. Wang has over 25 years of experience in the pharmaceutical industry. Previously, he was the Principal Research Scientist at Wyeth (acquired by Pfizer in 2009). Where he led multi-discipline drug discovery teams in anti-cancer and anti-inflammation research.
Dr. Luyan Zhang, SVP
PhD in Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College (1996)
Postdoc research at Shanghai Institute of Organic Chemistry (SIOC) (1996-1999)
Dr. Zhang had been working at Parke-Davis/Warner-Lambert Company (1999-2001, later acquired by Pfizer in 2000), Neurogen Corporation (2001-2009).
Dr. Jonathan Y. Gao, SVP
PhD in Organic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
Dr. Gao has more than 20 years of experience in lead identification and optimization in drug discovery, as well as extensive knowledge in heterocyclic chemistry, parallel synthesis, asymmetric synthesis, and other modern synthetic chemistry. Prior to joining Medinoah, he was research fellow at Neurogen Corporation (acquired by Ligand Pharmaceuticals Inc. in 2009). He also co-founded Allichem LLC. in 2008 where he was in charge of CRO operation in small molecule drug discovery.
Dr. Cindy J. Zhou R&D Director
PhD in Chemistry, University of Maryland College Park, USA
Dr. Zhou began her career with Teva USA and Purdue University Center for Drug Discovery, where she was involved early discovery and development, as well as analytical method development and testing. She came to the Medinoah after serving as senior scientist in Brunswick Laboratories, with experience in CRO project management and business development.